Evidence map›Paper›PMID 34755438›Full record

ArticleHIV medicine2022

Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.

Zahra Reynolds, Suzanne M McCluskey, Mahomed Yunus S Moosa, Rebecca F Gilbert, Selvan Pillay, Isaac Aturinda, Kevin L Ard, Winnie Muyindike, Nicholas Musinguzi, Godfrey Masette and 10 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02787499 (Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02787499 nacompletednot on this map

Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa

TypeinterventionalSponsorMassachusetts General HospitalRan2016 to 2020Enrolled840ConditionsHIV, AIDSArmsHIV-1 RNA Resistance Testing
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 4 countries.

Zahra ReynoldsMassachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-0668-6798
Suzanne M McCluskeyMassachusetts General Hospital, Boston, MA, USA.
Mahomed Yunus S MoosaUniversity of KwaZulu-Natal, Durban, South Africa.
Rebecca F GilbertMassachusetts General Hospital, Boston, MA, USA.
Selvan PillayUniversity of KwaZulu-Natal, Durban, South Africa.
Isaac AturindaMbarara University of Science and Technology, Mbarara, Uganda.
Kevin L ArdMassachusetts General Hospital, Boston, MA, USA.
Winnie MuyindikeMbarara University of Science and Technology, Mbarara, Uganda.
Nicholas MusinguziMbarara University of Science and Technology, Mbarara, Uganda.
Godfrey MasetteMbarara University of Science and Technology, Mbarara, Uganda.
Pravi MoodleyUniversity of KwaZulu-Natal, Durban, South Africa.
Jaysingh BrijkumarUniversity of KwaZulu-Natal, Durban, South Africa.
Tamlyn RautenbergGriffith University, Brisbane, QLD, Australia.
Gavin GeorgeUniversity of KwaZulu-Natal, Durban, South Africa.
Brent A JohnsonDepartment of Biostatistics and Computation Biology, University of Rochester, Rochester, NY, USA.
Rajesh T GandhiMassachusetts General Hospital, Boston, MA, USA.
Henry SunpathUniversity of KwaZulu-Natal, Durban, South Africa.
Vincent C MarconiEmory University School of Medicine, Atlanta, GA, USA.
Mwebesa Bosco BwanaMbarara University of Science and Technology, Mbarara, Uganda.
Mark J SiednerMassachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-3506-842X
Mbarara University of Science and Technology · UGUniversity of KwaZulu-Natal · ZAHarvard University · USMassachusetts General Hospital · USEmory Healthcare · USGriffith University · AUNational Health Laboratory Service · ZAUniversity of Rochester · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous systemR01MH128158 · NIMH · EMORY UNIVERSITY · PI Christina Gavegnano, Vincent Charles Marconi · 2022 to 2026
$3.2M
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trialR01AI124718 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MUYINDIKE, WINNIE, SIEDNER, MARK J · 2016 to 2020
$3.0M
Antiretroviral drug resistance in KwaZulu NatalR01AI098558 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KURITZKES, DANIEL R., MARCONI, VINCENT CHARLES · 2013 to 2017
$2.3M
Virologic and pharmacologic determinants of dolutegravir failure in East AfricaK23AI143470 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MCCLUSKEY, SUZANNE · 2019 to 2023
$1.0M
NIAID NIH HHS K23 AI143470NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI098558NIAID NIH HHS R01 AI124718NIAID NIH HHS T32 AI007387NIAID NIH HHS UM1 AI069412NIMH NIH HHS R01 MH128158
6 · The paper itself

Abstract

objectivesHIV virological failure remains a major threat to programme success in sub-Saharan Africa. While HIV drug resistance (HIVDR) and inadequate adherence are the main drivers of virological failure, the individual, clinical and health system characteristics that lead to poor outcomes are not well understood. The objective of this paper is to identify those characteristics among people failing first-line antiretroviral therapy (ART).

methodsWe enrolled a cohort of adults in HIV care experiencing virological failure on first-line ART at five sites and used standard statistical methods to characterize them with a focus on three domains: individual/demographic, clinical, and health system, and compared each by country of enrolment.

resultsOf 840 participants, 51% were women, the median duration on ART was 3.2 years [interquartile range (IQR) 1.1, 6.4 years] and the median CD4 cell count prior to failure was 281 cells/µL (IQR 121, 457 cells/µL). More than half of participants [53%; 95% confidence interval (CI) 49-56%] stated that they had > 90% adherence and 75% (95% CI 72-77%) took their ART on time all or most of the time. Conversely, the vast majority (90%; 95% CI 86-92%) with a completed genotypic drug resistance test had any HIV drug resistance. This population had high health system use, reporting a median of 3 (IQR 2.6) health care visits and a median of 1 (IQR 1.1) hospitalization in the preceding 6 months.

conclusionsPatients failing first-line ART in sub-Saharan Africa generally report high rates of adherence to ART, have extremely high rates of HIV drug resistance and utilize significant health care resources. Health systems interventions to promptly detect and manage treatment failure will be a prerequisite to establishing control of the HIV epidemic.

Indexed as

Anti-HIV AgentsHIV InfectionsAdultCD4 Lymphocyte CountDrug Resistance, ViralFemaleHumansSouth AfricaTreatment FailureUgandaViral LoadAnti-HIV AgentsAfricafirst-lineHIV drug resistancetreatment failurevirological failure

Identifiers

PMID34755438
PMCPMC9010349
OpenAlexW3213735842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.